JP2024501430A5 - - Google Patents
Info
- Publication number
- JP2024501430A5 JP2024501430A5 JP2023533928A JP2023533928A JP2024501430A5 JP 2024501430 A5 JP2024501430 A5 JP 2024501430A5 JP 2023533928 A JP2023533928 A JP 2023533928A JP 2023533928 A JP2023533928 A JP 2023533928A JP 2024501430 A5 JP2024501430 A5 JP 2024501430A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- composition according
- seq
- bdca2 antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121194P | 2020-12-03 | 2020-12-03 | |
| US63/121,194 | 2020-12-03 | ||
| PCT/US2021/061764 WO2022120144A1 (en) | 2020-12-03 | 2021-12-03 | Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501430A JP2024501430A (ja) | 2024-01-12 |
| JP2024501430A5 true JP2024501430A5 (https=) | 2024-12-09 |
Family
ID=79024222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533928A Pending JP2024501430A (ja) | 2020-12-03 | 2021-12-03 | 皮膚エリテマトーデス及び全身性エリテマトーデスの治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240018246A1 (https=) |
| EP (1) | EP4255392A1 (https=) |
| JP (1) | JP2024501430A (https=) |
| KR (1) | KR20230119664A (https=) |
| CN (1) | CN116963716A (https=) |
| AR (1) | AR124247A1 (https=) |
| AU (1) | AU2021391803A1 (https=) |
| CA (1) | CA3203971A1 (https=) |
| CL (1) | CL2023001562A1 (https=) |
| CO (1) | CO2023008272A2 (https=) |
| IL (1) | IL303279A (https=) |
| MX (1) | MX2023006474A (https=) |
| PE (1) | PE20231678A1 (https=) |
| TW (1) | TW202222829A (https=) |
| WO (1) | WO2022120144A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118638234B (zh) * | 2024-07-04 | 2025-10-14 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1454215B (zh) * | 1999-11-15 | 2013-01-02 | 米勒腾尼生物技术有限公司 | 树突状细胞特异的抗原结合片段、组合物及其使用方法、被其识别的抗原及由其获得的细胞 |
| AU2013359419B2 (en) * | 2012-12-10 | 2018-03-15 | Biogen Ma Inc. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
| CN109535254B (zh) * | 2013-12-24 | 2022-06-24 | 安斯泰来制药株式会社 | 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物 |
| CN109475623B (zh) | 2016-04-28 | 2023-05-26 | 比奥根Ma公司 | 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案 |
-
2021
- 2021-12-03 AU AU2021391803A patent/AU2021391803A1/en active Pending
- 2021-12-03 IL IL303279A patent/IL303279A/en unknown
- 2021-12-03 EP EP21827347.2A patent/EP4255392A1/en active Pending
- 2021-12-03 TW TW110145254A patent/TW202222829A/zh unknown
- 2021-12-03 MX MX2023006474A patent/MX2023006474A/es unknown
- 2021-12-03 KR KR1020237022397A patent/KR20230119664A/ko active Pending
- 2021-12-03 JP JP2023533928A patent/JP2024501430A/ja active Pending
- 2021-12-03 CA CA3203971A patent/CA3203971A1/en active Pending
- 2021-12-03 US US18/038,911 patent/US20240018246A1/en active Pending
- 2021-12-03 WO PCT/US2021/061764 patent/WO2022120144A1/en not_active Ceased
- 2021-12-03 CN CN202180091232.0A patent/CN116963716A/zh active Pending
- 2021-12-03 AR ARP210103370A patent/AR124247A1/es unknown
- 2021-12-03 PE PE2023001760A patent/PE20231678A1/es unknown
-
2023
- 2023-05-31 CL CL2023001562A patent/CL2023001562A1/es unknown
- 2023-06-23 CO CONC2023/0008272A patent/CO2023008272A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230159628A1 (en) | Anti-CGRP Antibody Formulation | |
| JP6396565B2 (ja) | 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤 | |
| AU2013255413B2 (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
| US12565526B2 (en) | Formulations of anti-RSV antibodies and methods of use thereof | |
| WO2023011502A1 (zh) | 含有抗il-4r抗体的稳定制剂 | |
| JP2024501430A5 (https=) | ||
| CN118056572A (zh) | 含有抗il-17抗体的稳定制剂 | |
| JP2025513510A (ja) | オクレリズマブを含む薬学的組成物とその用途 | |
| KR20240100493A (ko) | 항-cd22 항체의 수성 제제 및 이의 용도 | |
| JP7621411B2 (ja) | 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品 | |
| JP2023532203A5 (https=) | ||
| CA3115708C (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| TWI771335B (zh) | 穩定藥學調配物 | |
| EP4334351A1 (en) | Treatment for systemic lupus erythematosus using anti-baffr antibodies | |
| CN120227455A (zh) | 包含与乙型肝炎病毒表面抗原（HBsAg）特异性结合的抗体组合物 | |
| OA17126A (en) | Pharmaceutical formulations of TNF-alpha antibodies |